

Table 10.1

Kaposi Sarcoma

Number of Cases

By SEER Location and Year of Diagnosis, 1975-2008

All Races, Males, All Ages

Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2008
SEER 9 ^b	134	79	326	888	1,573	2,131	2,232	2,057	1,801	839	391	399	331	366	499
SEER 9 except SF-Oakland	102	44	85	260	427	776	841	976	874	463	244	265	221	243	363
San Francisco- Oakland SMSA ^c	32	35	241	628	1,146	1,355	1,391	1,081	927	376	147	134	110	123	136
San Francisco City/County	15	21	201	540	955	1,076	1,089	792	690	253	86	79	69	80	90

Age-Adjusted Cancer Incidence Rates^a

By SEER Location and Year of Diagnosis, 1975-2008

All Races, Males, All Ages

Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2008
SEER 9 ^b	0.4	0.5	1.7	4.2	7.1	9.2	9.3	8.2	7.0	3.2	1.5	1.5	1.3	1.4	1.2
SEER 9 except SF-Oakland	0.4	0.4	0.6	1.5	2.3	4.0	4.2	4.6	4.0	2.1	1.1	1.2	1.0	1.1	1.1
San Francisco- Oakland SMSA ^c	0.7	1.3	7.0	17.2	30.0	33.9	34.0	25.6	22.0	8.9	3.5	3.0	2.6	2.8	2.1
San Francisco City/County	1.1	3.1	25.1	65.3	111.3	124.5	125.7	89.1	77.5	28.2	9.4	8.5	7.5	8.7	6.5

^a Rates are per 100,000 males and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).^b The SEER 9 areas are San Francisco-Oakland SMSA, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.^c The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Kaposi Sarcoma.

- Statistic not shown. Rate based on less than 4 cases for the time interval.

Table 10.2

Kaposi Sarcoma

Number of Cases

By SEER Location and Year of Diagnosis, 1975-2008

All Races, Males, Ages 20-54

SEER Location	Year of Diagnosis														
	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2008
SEER 9 ^b	13	26	254	806	1,480	1,994	2,103	1,922	1,676	754	318	345	258	305	393
SEER 9 except SF-Oakland	11	5	35	207	378	695	772	910	809	410	197	226	182	200	290
San Francisco- Oakland SMSA ^c	<4	21	219	599	1,102	1,299	1,331	1,012	867	344	121	119	76	105	103
San Francisco City/County	<4	18	193	520	924	1,040	1,051	748	649	236	76	73	52	71	77

Age-Adjusted Cancer Incidence Rates^a

By SEER Location and Year of Diagnosis, 1975-2008

All Races, Males, Ages 20-54

SEER Location	Year of Diagnosis														
	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2008
SEER 9 ^b	0.1	0.3	2.4	7.4	13.1	16.9	17.1	14.9	12.7	5.6	2.3	2.5	1.9	2.2	1.9
SEER 9 except SF-Oakland	0.1	0.1	0.4	2.2	3.9	6.9	7.4	8.4	7.2	3.6	1.7	2.0	1.6	1.7	1.7
San Francisco- Oakland SMSA ^c	-	1.3	12.1	32.3	57.3	64.4	63.9	46.8	40.2	15.8	5.4	5.2	3.3	4.7	3.1
San Francisco City/County	-	5.3	47.8	125.1	214.0	238.8	240.3	165.3	142.7	51.5	16.1	15.5	10.7	15.3	10.9

^a Rates are per 100,000 males aged 20-54 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b The SEER 9 areas are San Francisco-Oakland SMSA, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

^c The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Kaposi Sarcoma.

- Statistic not shown. Rate based on less than 4 cases for the time interval.

Table 10.3

Kaposi Sarcoma

Number of Cases

By SEER Location and Year of Diagnosis, 1975-2008

All Races, Males, Ages 55+

Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2008
SEER 9 ^b	121	53	71	81	92	135	129	134	125	85	73	53	73	60	106
SEER 9 except SF-Oakland	91	39	49	53	49	81	69	65	65	53	47	38	39	42	73
San Francisco- Oakland SMSA ^c	30	14	22	28	43	54	60	69	60	32	26	15	34	18	33
San Francisco City/County	14	<4	8	20	31	35	38	44	41	17	10	6	17	9	13

Age-Adjusted Cancer Incidence Rates^a

By SEER Location and Year of Diagnosis, 1975-2008

All Races, Males, Ages 55+

Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2008
SEER 9 ^b	1.9	1.9	2.4	2.4	2.5	3.6	3.6	3.3	3.0	2.1	1.7	1.3	1.5	1.2	1.3
SEER 9 except SF-Oakland	1.7	1.7	2.0	2.0	1.8	2.7	2.4	2.0	1.9	1.6	1.3	1.1	1.0	1.0	1.1
San Francisco- Oakland SMSA ^c	2.9	3.1	4.6	4.7	6.4	8.1	9.6	10.4	8.8	4.8	3.7	2.1	4.4	2.2	2.6
San Francisco City/County	4.7	-	5.6	12.9	20.5	23.5	26.4	30.5	29.0	11.5	6.7	3.8	10.2	5.0	4.7

^a Rates are per 100,000 males aged 55+ and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b The SEER 9 areas are San Francisco-Oakland SMSA, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

^c The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Kaposi Sarcoma.

- Statistic not shown. Rate based on less than 4 cases for the time interval.

Table 10.4
Kaposi Sarcoma

Age-adjusted SEER Incidence^a Rates by Year, Race and Sex

Year of Diagnosis:	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
1975	0.23	0.56	-	0.22	0.56	-	-	-	-
1976	0.25	0.47	-	0.24	0.48	-	-	-	-
1977	0.29	0.54	-	0.30	0.55	-	-	-	-
1978	0.24	0.35	0.17	0.23	0.34	-	-	-	-
1979	0.18	0.30	-	0.18	0.30	-	-	-	-
1980	0.28	0.56	-	0.30	0.60	-	-	-	-
1981	0.31	0.54	-	0.34	0.61	-	-	-	-
1982	0.65	1.20	0.18	0.71	1.32	0.18	-	-	-
1983	1.07	2.19	-	1.19	2.40	-	-	-	-
1984	1.81	3.59	-	1.99	3.91	-	1.27	2.89	-
1985	2.46	4.86	0.16	2.80	5.47	0.18	1.09	2.24	-
1986	3.27	6.54	-	3.71	7.34	-	1.65	3.59	-
1987	3.80	7.61	-	4.25	8.44	-	2.09	4.29	-
1988	4.42	8.86	0.15	4.82	9.55	0.15	3.40	7.28	-
1989	4.76	9.52	0.14	5.13	10.17	-	4.57	9.68	-
1990	4.61	9.21	0.18	5.03	9.99	0.15	3.65	7.54	-
1991	4.70	9.40	0.19	5.04	10.00	0.18	4.59	9.54	-
1992	4.38	8.69	0.18	4.60	9.03	0.18	4.97	10.48	-
1993	3.86	7.64	0.17	4.05	7.96	0.15	4.28	8.59	-
1994	3.79	7.47	0.17	3.88	7.59	0.13	4.15	8.42	-
1995	3.29	6.45	0.20	3.28	6.37	0.17	4.90	10.19	-
1996	2.23	4.40	0.16	2.01	3.99	-	4.61	9.09	-
1997	1.08	2.09	0.14	0.92	1.78	-	2.67	5.31	-
1998	0.81	1.57	-	0.69	1.33	-	1.79	3.78	-
1999	0.78	1.47	0.14	0.66	1.24	-	1.94	3.72	-
2000	0.80	1.55	-	0.67	1.30	-	1.98	4.00	-
2001	0.82	1.49	0.18	0.67	1.19	0.15	1.94	3.80	-
2002	0.67	1.26	0.11	0.56	1.04	-	1.50	3.02	-
2003	0.66	1.26	-	0.59	1.09	-	1.47	3.10	-
2004	0.69	1.34	-	0.59	1.14	-	1.66	3.34	-
2005	0.75	1.42	0.12	0.58	1.10	-	1.93	3.78	-
2006	0.58	1.12	-	0.49	0.93	-	1.29	2.73	-
2007	0.66	1.26	-	0.55	1.02	-	1.51	3.15	-
2008	0.66	1.28	-	0.53	1.05	-	1.61	3.05	-
1975-2008	1.80	3.55	0.13	1.87	3.66	0.12	2.20	4.49	0.24

^a SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).
Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 10.5
Kaposi Sarcoma

SEER Incidence^a Rates, Age-Adjusted and Age-Specific Rates, by Race and Sex

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>SEER Incidence</u>									
<u>Age at Diagnosis</u>									
Age-Adjusted Rates, 2004-2008									
All ages	0.6	1.2	0.1	0.5	1.0	0.1	1.2	2.4	0.2
Under 65	0.6	1.1	0.0	0.5	0.9	0.0	1.3	2.5	0.2
65 and over	1.0	1.8	0.5	1.0	1.8	0.5	0.9	1.4	-
All ages (IARC world std) ^b	0.5	0.9	0.1	0.4	0.8	0.0	1.0	1.9	0.2
Age-Specific Rates, 2004-2008									
<1	-	-	-	-	-	-	-	-	-
1-4	-	-	-	-	-	-	-	-	-
5-9	-	-	-	-	-	-	-	-	-
10-14	-	-	-	-	-	-	-	-	-
15-19	-	-	-	-	-	-	-	-	-
20-24	0.2	0.3	-	0.1	0.2	-	0.6	1.2	-
25-29	0.5	0.9	-	0.4	0.7	-	1.6	3.0	-
30-34	0.8	1.6	-	0.7	1.3	-	2.3	4.4	-
35-39	1.3	2.6	-	1.1	2.2	-	3.3	6.5	-
40-44	1.4	2.8	-	1.2	2.4	-	3.4	6.9	-
45-49	1.0	2.0	-	0.9	1.8	-	2.0	3.8	-
50-54	0.6	1.2	-	0.6	1.1	-	1.1	2.2	-
55-59	0.5	0.9	-	0.4	0.9	-	-	-	-
60-64	0.5	0.8	-	0.4	0.8	-	-	-	-
65-69	0.6	1.1	-	0.6	1.1	-	-	-	-
70-74	0.7	1.1	0.4	0.8	1.3	0.4	-	-	-
75-79	1.0	1.9	0.4	0.9	1.7	-	-	-	-
80-84	1.4	2.1	1.0	1.4	2.1	0.9	-	-	-
85+	2.1	3.9	1.2	2.1	4.0	1.2	-	-	-

^a SEER 17 areas. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130), unless noted.

^b Rates are per 100,000 and are age-adjusted to the IARC world standard population.

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 10.6
Kaposi Sarcoma

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	-	-	-	-	-	-
1970-1973 ^a	-	-	-	-	-	-	-	-	-
1975-1977 ^b	82.2 ^f	82.0 ^f	-	81.6 ^f	80.2 ^f	-	-	-	-
1978-1980 ^b	78.1 ^f	79.1 ^f	73.1 ^g	77.4 ^f	77.5 ^f	72.9 ^g	-	-	-
1981-1983 ^b	35.9	33.2	70.8 ^g	34.3	31.6	68.7 ^g	-	-	-
1984-1986 ^b	12.8	11.5	70.9 ^g	12.5	11.2	70.7 ^g	16.8	15.7	-
1987-1989 ^b	9.9	9.2	69.0 ^g	9.4	8.8	72.3 ^g	12.0	10.8	-
1990-1992 ^b	9.4	8.7	52.6 ^f	9.0	8.4	52.3 ^f	11.6	10.6	-
1993-1995 ^b	21.7	21.0	52.2 ^f	22.3	21.5	60.0 ^g	16.3	15.4	-
1996-2000 ^b	53.0	52.2	68.5 ^f	58.0	56.7	83.6 ^g	39.8	39.6	-
2001-2007 ^b	66.9 ^e	66.3 ^e	69.7 ^f	76.1 ^e	74.6	79.3 ^f	47.7	48.7	-
5-Year Period Survival (Percent) ^{cd}									
2007	68.0	67.5	74.1	73.4	72.5	80.3	48.8	49.1	-
5-Year Relative Survival (Percent), 2001-2007 ^c									
Age at Diagnosis:									
Ages <45	61.7	62.1	41.4 ^f	66.6	66.6	-	48.4	49.5	25.4 ^g
Ages 45-54	63.4	64.4	-	66.7	67.4	-	48.5 ^f	50.5 ^f	-
Ages 55-64	76.0	76.8	-	78.3	78.3	-	46.7 ^g	48.0 ^g	-
Ages 65-74	83.9	86.3	68.8 ^g	82.4	84.5	68.1 ^g	-	-	-
Ages 75+	90.1	94.2 ^f	79.6 ^f	91.6	94.9 ^f	82.3 ^f	-	-	-
Ages <65	63.3	63.9	41.4 ^f	67.8	67.9	60.4 ^g	48.4	49.7	26.6 ^f
Ages 65+	88.4	92.0	78.4 ^f	88.7	92.1	80.3 ^f	87.3 ^f	-	-

^a Based on End Results data from a series of hospital registries and one population-based registry.
^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2008.
^c SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Based on follow-up of patients into 2008.
^d Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).
The difference between 1975-1977 and 2001-2007 is statistically significant (p<.05).
^e The standard error is between 5 and 10 percentage points.
^f The standard error is greater than 10 percentage points.
^g - Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 10.7
Kaposi Sarcoma

SEER^a Relative Survival (Percent)
By Year of Diagnosis

All Races, Males and Females

Survival Time	Year of Diagnosis																				
	1975- 1979	1980- 1984	1985- 1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
1-year	95.6	66.9	60.2	61.9	62.8	63.3	59.2	55.9	62.3	69.6	73.9	74.0	76.6	74.3	80.2	78.0	74.9	82.5	81.4	80.6	82.4
2-year	90.1	44.9	34.0	33.5	30.5	28.7	30.4	27.8	47.0	60.5	65.0	65.2	65.0	67.8	72.9	71.6	72.0	73.9	77.9	77.1	
3-year	89.0	36.0	20.1	20.0	15.6	16.6	19.7	21.1	42.8	54.5	61.9	60.7	61.3	61.3	67.3	67.0	66.3	70.7	74.4		
4-year	84.2	31.7	13.9	14.7	11.1	11.2	15.6	18.6	38.7	51.5	58.6	58.5	56.5	57.1	64.4	65.9	64.4	69.2			
5-year	84.2	28.0	10.4	10.1	8.8	9.3	14.1	17.5	35.6	48.2	56.5	58.1	55.7	54.1	63.8	59.3	64.3				
6-year	78.8	24.4	8.8	8.0	7.8	8.7	13.8	16.3	35.0	45.6	54.2	55.2	53.1	52.5	63.2	57.5					
7-year	76.9	23.3	7.6	7.5	7.6	8.0	13.2	15.2	33.4	44.7	50.0	52.7	52.6	52.5	62.4						
8-year	76.9	20.5	6.7	7.0	7.3	7.8	12.7	14.8	32.1	44.5	47.4	50.6	52.1	51.9							
9-year	76.9	19.1	6.0	6.8	6.9	7.7	12.5	14.1	31.0	42.6	43.9	49.4	52.1								
10-year	76.9	16.9	5.7	6.8	6.8	7.4	12.4	13.8	29.8	42.5	43.2	49.4									
11-year	74.9	15.6	5.5	6.7	6.7	7.4	11.8	13.5	28.6	41.9	41.9										
12-year	74.9	15.3	5.3	6.7	6.7	7.3	11.7	13.4	27.8	41.6											
13-year	74.9	14.7	5.0	6.7	6.5	7.2	11.7	13.4	27.3												
14-year	74.9	14.7	4.8	6.3	6.5	6.9	11.7	13.2													
15-year	74.9	14.7	4.7	5.8	6.5	6.6	11.6														
16-year	74.9	14.7	4.6	5.7	6.5	6.5															
17-year	74.9	14.4	4.6	5.6	6.4																
18-year	74.9	13.1	4.6	5.2																	
19-year	74.9	13.1	4.4																		
20-year	74.9	13.1																			

^a Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 10.8
Kaposi Sarcoma

SEER^a Relative Survival (Percent)
By Year of Diagnosis

All Races, Males

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
Survival Time																					
1-year	95.8	65.2	59.9	61.5	62.4	63.1	59.0	55.4	61.4	69.4	73.9	73.3	76.7	73.6	79.3	76.8	75.1	81.3	82.4	79.9	82.5
2-year	89.6	42.2	33.3	33.0	29.7	28.2	29.4	27.2	45.7	59.9	64.4	63.6	64.5	66.0	73.0	70.4	71.9	72.6	78.6	76.0	
3-year	87.3	33.5	19.3	19.3	14.7	16.2	19.0	20.6	41.8	54.2	60.9	59.2	60.8	59.8	68.3	66.1	66.5	69.0	75.4		
4-year	84.3	29.2	13.0	13.9	10.1	10.9	14.8	18.0	37.6	51.0	57.1	56.5	55.5	56.3	64.7	65.6	64.3	67.1			
5-year	84.2	25.7	9.6	9.3	7.8	8.9	13.3	16.9	35.0	47.9	56.0	55.7	54.4	53.7	63.5	58.9	64.0				
6-year	75.5	22.0	7.9	7.3	6.9	8.4	12.9	15.7	34.3	45.4	53.5	53.5	51.5	52.6	63.1	57.2					
7-year	74.3	20.6	6.7	6.8	6.6	7.6	12.5	14.6	32.5	44.4	49.9	51.9	50.7	52.6	63.0						
8-year	74.3	18.3	5.9	6.3	6.3	7.5	12.0	14.2	31.3	44.1	46.9	50.9	50.6	51.8							
9-year	74.3	17.1	5.2	6.1	5.8	7.4	11.8	13.5	30.3	42.2	43.6	49.7	50.6								
10-year	74.3	15.1	5.0	6.1	5.7	7.1	11.6	13.3	29.2	42.0	42.8	49.7									
11-year	69.1	13.8	4.8	6.0	5.5	7.1	11.0	12.9	28.1	41.5	41.4										
12-year	69.1	13.6	4.7	6.0	5.4	7.0	10.9	12.8	27.2	41.0											
13-year	69.1	13.0	4.4	6.0	5.2	6.9	10.9	12.7	26.7												
14-year	69.1	13.0	4.3	5.6	5.2	6.6	10.9	12.4													
15-year	69.1	12.9	4.2	5.3	5.2	6.3	10.8														
16-year	69.1	12.7	4.1	5.2	5.1	6.1															
17-year	69.1	12.7	4.1	5.1	5.0																
18-year	69.1	12.4	4.1	4.8																	
19-year	69.1	12.4	3.9																		
20-year	69.1	12.4																			

^a Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 10.9
Kaposi Sarcoma

SEER^a Relative Survival (Percent)
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
Survival Time																					
1-year	93.9	91.7	83.7	79.9	90.2	74.9	71.5	82.0	87.6	78.6	74.2	85.5	75.7	81.8	87.3	89.4	69.4	100.0	64.6	89.8	80.4
2-year	90.9	85.7	79.0	56.3	79.9	53.9	71.5	56.2	86.3	78.6	69.5	85.5	69.8	81.8	69.3	81.1	69.4	97.0	64.6	89.8	
3-year	90.9	74.9	74.8	56.3	75.4	44.5	52.9	50.0	74.8	64.6	69.5	85.4	65.9	77.7	54.8	71.3	62.2	97.0	57.3		
4-year	83.6	71.3	74.3	52.0	75.4	33.1	52.9	46.0	70.4	64.6	69.5	85.4	65.9	67.4	54.8	63.1	62.2	97.0			
5-year	81.5	64.4	74.1	49.9	73.2	33.1	52.9	46.0	50.4	55.2	63.0	85.4	65.9	57.6	54.8	59.0	62.2				
6-year	81.5	62.6	74.1	45.0	69.4	28.2	52.9	45.6	50.4	49.7	63.0	81.2	65.9	47.5	54.8	56.8					
7-year	81.5	62.6	74.1	45.0	69.4	28.2	47.8	40.9	50.4	49.7	51.5	54.7	65.9	47.5	52.4						
8-year	81.5	55.2	66.7	45.0	69.4	24.4	47.8	40.9	50.4	49.7	51.5	19.6	65.9	47.5							
9-year	81.5	52.0	66.7	45.0	69.4	24.4	44.3	38.9	47.7	49.7	45.1	0.0	65.9								
10-year	81.5	46.3	60.4	45.0	69.4	24.4	44.3	38.9	44.8	49.7	45.1	0.0									
11-year	81.5	43.6	58.3	40.8	69.4	24.4	44.3	38.9	37.8	49.7	45.1										
12-year	81.5	43.1	49.5	40.8	69.4	24.4	44.3	38.9	37.8	49.7											
13-year	81.5	42.2	44.7	40.8	69.4	24.4	44.3	38.9	37.8												
14-year	81.5	42.2	32.9	40.8	69.4	24.4	44.3	38.9													
15-year	81.5	42.2	28.0	19.3	69.4	24.4	44.3														
16-year	81.5	42.2	28.0	19.3	69.4	24.4															
17-year	81.5	30.2	28.0	19.3	69.4																
18-year	80.9	17.1	28.0	19.3																	
19-year	80.9	17.1	28.0																		
20-year	80.9	17.1																			

^a Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 10.10
Kaposi Sarcoma

Risk of Being Diagnosed With Cancer in 10, 20 and 30 Years,
Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age, and
Lifetime Risk of Dying from Cancer Given Alive at Current Age
Both Sexes, 2006-2008 By Race/Ethnicity

Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer	Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer
		+10 yrs	+20 yrs	+30 yrs	Ever				+10 yrs	+20 yrs	+30 yrs	Ever	
All Races	0	0.00	0.00	0.00	0.05	0.00	Asian/ Pacific Islander	0	0.00	0.00	0.00	0.02	0.00
	10	0.00	0.00	0.01	0.05	0.00		10	0.00	0.00	0.00	0.02	0.00
	20	0.00	0.01	0.02	0.05	0.00		20	0.00	0.00	0.01	0.02	0.00
	30	0.01	0.02	0.03	0.04	0.00		30	0.00	0.01	0.01	0.02	0.00
	40	0.01	0.02	0.02	0.04	0.00		40	0.00	0.01	0.01	0.02	0.00
	50	0.01	0.01	0.02	0.02	0.00		50	0.00	0.00	0.01	0.01	0.00
	60	0.01	0.01	0.02	0.02	0.00		60	0.00	0.00	0.01	0.01	0.00
	70	0.01	0.01	-	0.02	0.00		70	0.00	0.01	-	0.01	0.00
80	0.01	-	-	0.01	0.00	80	0.01	-	-	0.01	0.00		
White	0	0.00	0.00	0.00	0.04	0.00	American Indian/ Alaska Native ^a	0	0.00	0.00	0.00	0.02	0.00
	10	0.00	0.00	0.01	0.04	0.00		10	0.00	0.00	0.00	0.02	0.00
	20	0.00	0.01	0.02	0.04	0.00		20	0.00	0.00	0.01	0.02	0.00
	30	0.01	0.02	0.02	0.04	0.00		30	0.00	0.01	0.01	0.02	0.00
	40	0.01	0.01	0.02	0.03	0.00		40	0.01	0.01	0.01	0.02	0.00
	50	0.00	0.01	0.02	0.02	0.00		50	0.00	0.00	0.01	0.01	0.00
	60	0.00	0.01	0.02	0.02	0.00		60	0.00	0.01	0.01	0.01	0.00
	70	0.01	0.01	-	0.02	0.00		70	0.01	0.01	-	0.01	0.00
80	0.01	-	-	0.01	0.00	80	0.00	-	-	0.00	0.00		
Black	0	0.00	0.00	0.01	0.08	0.01	Hispanic ^b	0	0.00	0.00	0.00	0.07	0.01
	10	0.00	0.01	0.03	0.08	0.01		10	0.00	0.00	0.01	0.07	0.01
	20	0.01	0.03	0.06	0.08	0.01		20	0.00	0.01	0.03	0.07	0.01
	30	0.02	0.05	0.05	0.07	0.01		30	0.01	0.02	0.03	0.06	0.01
	40	0.02	0.03	0.04	0.05	0.01		40	0.01	0.02	0.03	0.06	0.00
	50	0.01	0.01	0.02	0.02	0.00		50	0.01	0.01	0.02	0.04	0.00
	60	0.01	0.01	0.02	0.02	0.00		60	0.01	0.02	0.03	0.04	0.00
	70	0.01	0.01	-	0.01	0.00		70	0.01	0.02	-	0.03	0.00
80	0.01	-	-	0.01	0.00	80	0.02	-	-	0.03	0.00		

Devcan Version 6.6.0, October 2011, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: Incidence data are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Mortality data are from the NCHS public use data file for the total US.

^a Underlying incidence and mortality data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

Underlying mortality data for Hispanics exclude deaths from the District of Columbia, Minnesota, New Hampshire and North Dakota.

- Statistic could not be calculated.

A percent of 0.00 represents a value that is below 0.005.

Table 10.11
Kaposi Sarcoma

Risk of Being Diagnosed With Cancer in 10, 20 and 30 Years,
Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age, and
Lifetime Risk of Dying from Cancer Given Alive at Current Age
Males, 2006-2008 By Race/Ethnicity

Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer	Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer
		+10 yrs	+20 yrs	+30 yrs	Ever				+10 yrs	+20 yrs	+30 yrs	Ever	
All Races	0	0.00	0.00	0.01	0.08	0.01	Asian/ Pacific Islander	0	0.00	0.00	0.00	0.03	0.00
	10	0.00	0.01	0.02	0.08	0.01		10	0.00	0.00	0.00	0.03	0.00
	20	0.01	0.02	0.05	0.08	0.01		20	0.00	0.00	0.01	0.03	0.00
	30	0.02	0.04	0.05	0.08	0.01		30	0.00	0.01	0.02	0.03	0.00
	40	0.02	0.03	0.04	0.06	0.00		40	0.01	0.01	0.02	0.03	0.00
	50	0.01	0.02	0.03	0.04	0.00		50	0.00	0.01	0.01	0.02	0.00
	60	0.01	0.02	0.03	0.03	0.00		60	0.00	0.01	0.02	0.02	0.00
	70	0.01	0.02	-	0.03	0.00		70	0.00	0.02	-	0.02	0.00
80	0.02	-	-	0.02	0.00	80	0.01	-	-	0.01	0.00		
White	0	0.00	0.00	0.00	0.07	0.00	American Indian/ Alaska Native ^a	0	0.00	0.00	0.00	0.02	0.00
	10	0.00	0.00	0.02	0.07	0.00		10	0.00	0.00	0.01	0.02	0.00
	20	0.00	0.02	0.04	0.07	0.00		20	0.00	0.01	0.02	0.02	0.00
	30	0.02	0.03	0.04	0.07	0.00		30	0.01	0.02	0.02	0.02	0.00
	40	0.02	0.03	0.04	0.06	0.00		40	0.01	0.02	0.02	0.02	0.00
	50	0.01	0.02	0.03	0.04	0.00		50	0.00	0.00	0.00	0.00	0.00
	60	0.01	0.02	0.03	0.03	0.00		60	0.00	0.00	0.00	0.00	0.00
	70	0.01	0.02	-	0.03	0.00		70	0.00	0.00	-	0.00	0.00
80	0.02	-	-	0.02	0.00	80	0.00	-	-	0.00	0.00		
Black	0	0.00	0.00	0.02	0.14	0.02	Hispanic ^b	0	0.00	0.00	0.01	0.12	0.01
	10	0.00	0.02	0.06	0.14	0.02		10	0.00	0.01	0.03	0.12	0.01
	20	0.02	0.06	0.11	0.14	0.02		20	0.01	0.03	0.05	0.12	0.01
	30	0.04	0.09	0.10	0.12	0.01		30	0.02	0.04	0.05	0.11	0.01
	40	0.05	0.06	0.07	0.08	0.01		40	0.02	0.04	0.05	0.09	0.01
	50	0.02	0.02	0.03	0.04	0.01		50	0.01	0.03	0.04	0.07	0.01
	60	0.01	0.02	0.02	0.03	0.00		60	0.02	0.03	0.05	0.06	0.01
	70	0.02	0.02	-	0.02	0.00		70	0.01	0.04	-	0.06	0.01
80	0.01	-	-	0.01	0.00	80	0.03	-	-	0.06	0.01		

Devcan Version 6.6.0, October 2011, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: Incidence data are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Mortality data are from the NCHS public use data file for the total US.

^a Underlying incidence and mortality data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

Underlying mortality data for Hispanics exclude deaths from the District of Columbia, Minnesota, New Hampshire and North Dakota.

- Statistic could not be calculated.

A percent of 0.00 represents a value that is below 0.005.

Table 10.12
Kaposi Sarcoma

Risk of Being Diagnosed With Cancer in 10, 20 and 30 Years,
Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age, and
Lifetime Risk of Dying from Cancer Given Alive at Current Age
Females, 2006-2008 By Race/Ethnicity

Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer	Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer
		+10 yrs	+20 yrs	+30 yrs	Ever				+10 yrs	+20 yrs	+30 yrs	Ever	
All Races	0	0.00	0.00	0.00	0.01	0.00	Asian/ Pacific Islander	0	0.00	0.00	0.00	0.00	0.00
	10	0.00	0.00	0.00	0.01	0.00		10	0.00	0.00	0.00	0.00	0.00
	20	0.00	0.00	0.00	0.01	0.00		20	0.00	0.00	0.00	0.00	0.00
	30	0.00	0.00	0.00	0.01	0.00		30	0.00	0.00	0.00	0.00	0.00
	40	0.00	0.00	0.00	0.01	0.00		40	0.00	0.00	0.00	0.00	0.00
	50	0.00	0.00	0.00	0.01	0.00		50	0.00	0.00	0.00	0.00	0.00
	60	0.00	0.00	0.01	0.01	0.00		60	0.00	0.00	0.00	0.00	0.00
	70	0.00	0.01	-	0.01	0.00		70	0.00	0.00	-	0.00	0.00
80	0.01	-	-	0.01	0.00	80	0.00	-	-	0.00	0.00		
White	0	0.00	0.00	0.00	0.01	0.00	American Indian/ Alaska Native ^a	0	0.00	0.00	0.00	0.02	0.00
	10	0.00	0.00	0.00	0.01	0.00		10	0.00	0.00	0.00	0.02	0.00
	20	0.00	0.00	0.00	0.01	0.00		20	0.00	0.00	0.00	0.02	0.00
	30	0.00	0.00	0.00	0.01	0.00		30	0.00	0.00	0.00	0.02	0.00
	40	0.00	0.00	0.00	0.01	0.00		40	0.00	0.00	0.00	0.02	0.00
	50	0.00	0.00	0.00	0.01	0.00		50	0.00	0.00	0.02	0.02	0.00
	60	0.00	0.00	0.01	0.01	0.00		60	0.00	0.02	0.02	0.02	0.00
	70	0.00	0.01	-	0.01	0.00		70	0.02	0.02	-	0.02	0.00
80	0.01	-	-	0.01	0.00	80	0.00	-	-	0.00	0.00		
Black	0	0.00	0.00	0.00	0.02	0.00	Hispanic ^b	0	0.00	0.00	0.00	0.02	0.00
	10	0.00	0.00	0.01	0.02	0.00		10	0.00	0.00	0.00	0.02	0.00
	20	0.00	0.01	0.01	0.02	0.00		20	0.00	0.00	0.00	0.02	0.00
	30	0.00	0.01	0.01	0.02	0.00		30	0.00	0.00	0.00	0.02	0.00
	40	0.00	0.00	0.01	0.01	0.00		40	0.00	0.00	0.00	0.02	0.00
	50	0.00	0.01	0.01	0.01	0.00		50	0.00	0.00	0.01	0.02	0.00
	60	0.00	0.01	0.01	0.01	0.00		60	0.00	0.01	0.02	0.02	0.00
	70	0.00	0.01	-	0.01	0.00		70	0.01	0.02	-	0.02	0.00
80	0.01	-	-	0.01	0.00	80	0.01	-	-	0.01	0.00		

Devcan Version 6.6.0, October 2011, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: Incidence data are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Mortality data are from the NCHS public use data file for the total US.

^a Underlying incidence and mortality data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

Underlying mortality data for Hispanics exclude deaths from the District of Columbia, Minnesota, New Hampshire and North Dakota.

- Statistic could not be calculated.

A percent of 0.00 represents a value that is below 0.005.

Table 10.13
Kaposi Sarcoma

SEER Incidence
Age-Adjusted Rates and Trends^a
By Race/Ethnicity and Sex

SEER Incidence	SEER 17 Areas ^b			SEER 13 Areas ^b			SEER 9 Areas ^b		
	Rate 2004-2008			Trend 1999-2008 ^c			Trend 1999-2008 ^d		
	Rate per 100,000 persons			AAPC (%)			AAPC (%)		
RACE/ETHNICITY	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Races	0.6	1.2	0.1	-3.0*	-2.8*	-6.6*	-2.0*	-1.9*	-6.8*
White	0.5	1.0	0.1	-2.8*	-2.7*	-	-2.0*	-2.0*	-5.6*
White Hispanic ^e	0.8	1.5	0.1	-5.8	-3.9	-	-	-	-
White Non-Hispanic ^e	0.5	0.9	0.1	-2.5	-2.6	-	-	-	-
Black	1.2	2.4	0.2	-3.9*	-3.9*	-	-3.1	-3.0	-
Asian/Pacific Islander	0.2	0.4	-	-	-	-	-	-	-
Amer Ind/Alaska Nat ^f	-	-	-	-	-	-	-	-	-
Hispanic ^e	0.8	1.5	0.2	-5.9	-3.9	-	-	-	-

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.5, April 2011, National Cancer Institute.

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

^a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130). Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia.

The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.

^c The 1999-2008 AAPC estimates are based on a Joinpoint analysis with up to 3 Joinpoints over diagnosis years 1992-2008.

^d The 1999-2008 AAPC estimates are based on a Joinpoint analysis with up to 5 Joinpoints over diagnosis years 1975-2008.

^e Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^f Incidence data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

* The APC is significantly different from zero (p<.05).

Table 10.14
Kaposi Sarcoma

Age-Adjusted SEER Incidence Rates^a
By Registry, Race and Sex

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>SEER Incidence Rates^a, 2004-2008</u>									
Atlanta & Rural Georgia	1.38	2.72	-	0.93	1.76	-	2.08	4.39	-
Atlanta	1.42	2.81	-	0.96	1.82	-	2.14	4.53	-
Rural Georgia	-	-	-	-	-	-	-	-	-
California	0.72	1.36	0.09	0.72	1.35	0.08	1.27	2.38	-
Greater Bay Area	0.95	1.81	0.11	1.11	2.08	-	1.94	3.66	-
San Francisco-Oakland	1.25	2.39	0.13	1.49	2.79	-	2.18	4.25	-
San Jose-Monterey	0.41	0.79	-	0.46	0.87	-	-	-	-
Los Angeles	1.06	2.10	0.09	1.13	2.19	0.10	1.27	2.70	-
Greater California	0.46	0.82	0.09	0.42	0.76	0.07	1.00	1.63	-
Connecticut	0.38	0.74	-	0.30	0.62	-	1.02	-	-
Detroit	0.48	0.88	0.13	0.27	0.47	-	0.90	1.86	-
Hawaii	0.45	0.83	-	0.95	-	-	-	-	-
Iowa	0.12	0.25	-	-	-	-	-	-	-
Kentucky	0.21	0.37	-	0.19	0.33	-	-	-	-
Louisiana	0.60	1.05	0.20	0.50	0.89	-	0.84	1.43	-
New Jersey	0.51	0.93	0.15	0.42	0.78	0.11	1.01	1.82	-
New Mexico	0.46	0.90	-	0.46	0.88	-	-	-	-
Seattle-Puget Sound	0.55	1.05	-	0.50	0.96	-	1.76	-	-
Utah	0.20	0.38	-	0.22	0.41	-	-	-	-
9 SEER Areas ^b	0.67	1.28	0.08	0.55	1.05	0.07	1.60	3.22	0.20
11 SEER Areas ^b	0.74	1.44	0.08	0.68	1.30	0.07	1.52	3.07	0.17
13 SEER Areas ^b	0.74	1.44	0.08	0.68	1.30	0.07	1.50	3.04	0.17
17 SEER Areas ^b	0.61	1.15	0.10	0.54	1.02	0.08	1.24	2.37	0.23

^a Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

^b The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

The SEER 11 areas comprise the SEER 9 areas plus San Jose-Monterey and Los Angeles.

The SEER 13 areas comprise the SEER 11 areas plus the Alaska Native Registry and Rural Georgia.

The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 10.15
Kaposi SarcomaEstimated United States Cancer Prevalence Counts^a on January 1, 2008
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <18 ^e	0 to <33 ^e	>=33 ^g	Complete ^h
<u>Race</u>	<u>Sex</u>										
All Races ^b	Both Sexes	6,212	5,026	7,147	1,933	617	204	20,361	22,104	+	+
	Males	5,793	4,683	6,912	1,791	584	134	19,173	20,791	+	+
	Females	419	343	235	142	33	70	1,188	1,313	+	+
White ^b	Both Sexes	4,509	3,628	5,908	1,600	509	171	15,633	17,087	+	+
	Males	4,186	3,381	5,741	1,490	487	101	14,731	16,071	+	+
	Females	323	247	167	110	22	70	902	1,016	+	+
Black ^b	Both Sexes	1,440	1,077	843	154	64	10	3,669	3,805	+	+
	Males	1,362	1,014	786	144	64	10	3,456	3,592	+	+
	Females	78	63	57	10	0	0	213	213	+	+
Asian/ Pacific Islander ^c	Both Sexes	93	83	83	+	+	+	267	+	+	+
	Males	88	83	83	+	+	+	262	+	+	+
	Females	5	0	0	+	+	+	5	+	+	+
Hispanic ^d	Both Sexes	1,228	970	1,193	+	+	+	3,659	+	+	+
	Males	1,168	901	1,168	+	+	+	3,481	+	+	+
	Females	60	69	25	+	+	+	178	+	+	+

Estimated prevalence percent^a on January 1, 2008, of the SEER 11 population diagnosed in the previous 18 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)									Age-Adjusted ^f	
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races ^c	Both Sexes	0.0072%	-	-	0.0009%	0.0068%	0.0196%	0.0142%	0.0081%	0.0071%	0.0130%	0.0072%
	Males	0.0140%	-	-	0.0018%	0.0131%	0.0385%	0.0286%	0.0159%	0.0139%	0.0247%	0.0141%
	Females	0.0007%	-	-	-	0.0002%	0.0007%	0.0004%	0.0010%	0.0017%	0.0065%	0.0006%
White ^c	Both Sexes	0.0073%	-	-	0.0006%	0.0063%	0.0195%	0.0146%	0.0083%	0.0078%	0.0132%	0.0072%
	Males	0.0140%	-	-	0.0012%	0.0119%	0.0377%	0.0292%	0.0161%	0.0149%	0.0251%	0.0139%
	Females	0.0007%	-	-	-	0.0002%	0.0006%	-	0.0011%	0.0021%	0.0067%	0.0006%
Black ^c	Both Sexes	0.0098%	-	-	0.0029%	0.0140%	0.0293%	0.0178%	0.0094%	0.0043%	0.0101%	0.0103%
	Males	0.0196%	-	-	0.0055%	0.0296%	0.0615%	0.0371%	0.0200%	0.0091%	-	0.0211%
	Females	0.0008%	-	-	-	-	-	0.0017%	-	-	0.0115%	0.0010%
Asian/ Pacific Islander ^c	Both Sexes	0.0018%	-	-	-	0.0015%	0.0041%	0.0041%	0.0016%	0.0029%	0.0059%	0.0018%
	Males	0.0037%	-	-	-	0.0031%	0.0082%	0.0089%	0.0035%	0.0068%	0.0136%	0.0039%
	Females	-	-	-	-	-	-	-	-	-	-	-
Hispanic ^d	Both Sexes	-	-	-	-	-	-	-	-	-	-	-
	Males	-	-	-	-	-	-	-	-	-	-	-
	Females	-	-	-	-	-	-	-	-	-	-	-

^a US 2008 cancer prevalence counts are based on 2008 cancer prevalence proportions from the SEER registries and 1/1/2008 US population estimates based on the average of 2007 and 2008 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

^{b c d} Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia.

^e Maximum limited-duration prevalence: 33 years for 1975-2008 SEER 9 data; 18 years for 1990-2008 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

^f Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.


^{g h i} (g) Cases diagnosed more than 33 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <33 and >=33. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Figure 10.1

All Cancer Sites vs Kaposi Sarcoma SEER Incidence Rates, 1975-2008 Males, Ages 20-54



Source: SEER 9 areas.
Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
Regression lines are calculated using the Joinpoint Regression Program Version 3.5, April 2011,
National Cancer Institute.

All SEER excluding San Francisco/Oakland Males, Ages 20-54 1975-2008

San Francisco/Oakland Males, Ages 20-54 1975-2008

San Francisco County/City Males, Ages 20-54 1975-2008






Figure 10.2

Source: SEER 9 areas. Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

^a Kaposi Sarcoma cases are excluded from Colon & Rectum, Lung & Bronchus, and Non-Hodgkin Lymphoma cases.